Fig. 1 · Structure
Documents & Downloads
Lifastuzumab vedotin
ADC
Lifastuzumab vedotin is an antibody-drug conjugate (ADC) targeting NaPi2b, composed of a humanized IgG1 monoclonal antibody linked to the antimitotic agent monomethyl auristatin E (MMAE). This conjugate disrupts microtubule dynamics, effectively inhibiting cell division. Lifastuzumab vedotin shows promise in the research of non-small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (PROC), offering valuable insights into targeted cancer therapies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| CAS Number | 1401812-88-1 |
| Applications | ADC |
| Synonyms | RG-7599; DNIB-0600A; NaPi2b-ADC |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.